Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/24950
Title: | Cytotoxic CD4+T Cells Drive Multiple Sclerosis Progression | Authors: | PEETERS, Liesbet VANHEUSDEN, Marjan SOMERS, Veerle VAN WIJMEERSCH, Bart STINISSEN, Piet BROUX, Bieke HELLINGS, Niels |
Issue Date: | 2017 | Publisher: | FRONTIERS MEDIA SA | Source: | FRONTIERS IN IMMUNOLOGY, 8, p. 1-7 (Art N° 1160) | Abstract: | Multiple sclerosis (MS) is the leading cause of chronic neurological disability in young adults. The clinical disease course of MS varies greatly between individuals, with some patients progressing much more rapidly than others, making prognosis almost impossible. We previously discovered that cytotoxic CD4+ Tcells (CD4+ CTL), identified by the loss of CD28, are able to migrate to sites of inflammation and that they contribute to tissue damage. Furthermore, in an animal model for MS, we showed that these cells are correlated with inflammation, demyelination, and disability. Therefore, we hypothesize that CD4+ CTL drive progression of MS and have prognostic value. To support this hypothesis, we investigated whether CD4+ CTL are correlated with worse clinical outcome and evaluated the prognostic value of these cells in MS. To this end, the percentage of CD4+ CD28null T cells was measured in the blood of 176 patients with relapsing-remitting MS (=baseline). Multimodal evoked potentials (EP) combining information on motoric, visual, and somatosensoric EP, as well as Kurtzke expanded disability status scale (EDSS) were used as outcome measurements at baseline and after 3 and 5 years. The baseline CD4+ CD28null T cell percentage is associated with EP (P = 0.003, R-2 = 0.28), indicating a link between these cells and disease severity. In addition, the baseline CD4+ CD28null T cell percentage has a prognostic value since it is associated with EP after 3 years (P = 0.005, R-2 = 0.29) and with EP and EDSS after 5 years (P = 0.008, R-2 = 0.42 and P = 0.003, R-2 = 0.27). To the best of our knowledge, this study provides the first direct link between the presence of CD4+ CTL and MS disease severity, as well as its prognostic value. Therefore, we further elaborate on two important research perspectives: 1 degrees investigating strategies to block or reverse pathways in the formation of these cells resulting in new treatments that slow down MS disease progression, 2 degrees including immunophenotyping in prediction modeling studies to aim for personalized medicine. | Notes: | [Peeters, Liesbet M.; Vanheusden, Marjan; Somers, Veerle; Van Wijmeersch, Bart; Stinissen, Piet; Broux, Bieke; Hellings, Niels] Hasselt Univ, Transnat Univ Limburg, Sch Life Sci, Biomed Res Inst, Diepenbeek, Belgium. | Keywords: | multiple sclerosis; prognosis; multimodal evoked potentials; CD4+CD28null T cells; personalized medicine; prognostic risk factor;multiple sclerosis; prognosis; multimodal evoked potentials; CD4+CD28null T cells; personalized medicine; prognostic risk factor | Document URI: | http://hdl.handle.net/1942/24950 | ISSN: | 1664-3224 | e-ISSN: | 1664-3224 | DOI: | 10.3389/fimmu.2017.01160 | ISI #: | 000411178200001 | Rights: | Copyright: © 2017 Peeters, Vanheusden, Somers, Van Wijmeersch, Stinissen, Broux and Hellings. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2018 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
peeters 1.pdf | Published version | 463.5 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
19
checked on Sep 5, 2020
WEB OF SCIENCETM
Citations
58
checked on Oct 12, 2024
Page view(s)
94
checked on Jul 15, 2022
Download(s)
104
checked on Jul 15, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.